Monitoring tyrosinaemia type I: Blood spot test for nitisinone (NTBC)

Clinica Chimica Acta

Volumn 412, Issue 1-2, 2011, Pages 134-138

  Sander, Johannes ^a   Janzen, Nils ^a,b   Terhardt, Michael ^a   Sander, Stefanie ^a   Gökcay, Gülden ^c   Demirkol, Mübeccel ^c   Ozer, Isil ^c   Peter, Michael ^a   Das, Anibh M ^b  

^a Screening Laboratory   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Blood spot testing; Monitoring therapy; Nitisinone; NTBC; Tyrosinaemia type I; Tyrosine

Indexed keywords

METHANOL; NITISINONE; SUCCINYLACETONE; TYROSINE;

ARTICLE; BLOOD ANALYSIS; BLOOD FILTER; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG MONITORING; FEMALE; FOLLOW UP; HUMAN; LIQUID PHASE MICROEXTRACTION; LOW DRUG DOSE; MALE; MASS SPECTROMETER; PRESCHOOL CHILD; PRIORITY JOURNAL; PROCESS DEVELOPMENT; QUANTITATIVE ANALYSIS; SCHOOL CHILD; TANDEM MASS SPECTROMETRY; TREATMENT DURATION; TYROSINEMIA; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

BLOOD CHEMICAL ANALYSIS; CYCLOHEXANONES; FOLLOW-UP STUDIES; HUMANS; MALE; NITROBENZOATES; SPECIMEN HANDLING; TREATMENT OUTCOME; TYROSINEMIAS;

EID: 78650512447     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.09.027     Document Type: Article

References (22)

1. Joshi S.N., Venugopalan P. Experience with NTBC therapy in hereditary tyrosinaemia type I: an alternative to liver transplantation. Ann Trop Paediatr 2004, 24:259-265.
2. Holme E., Lindstedt S. Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione). J Inherit Metab Dis 1998, 21:507-517.
3. Santra S., Baumann U. Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1. Expert Opin Pharmacother 2008, 9:1229-1236.
4. McKiernan P.J. Nitisinone in the treatment of hereditary tyrosinaemia type 1. Drugs 2006, 66:743-750.
5. Masurel-Paulet A., Poggi-Bach J., Rolland M.O., et al. NTBC treatment in tyrosinaemia type I: long-term outcome in French patients. J Inherit Metab Dis 2008, 31:81-87.
6. Paradis K., Weber A., Seidman E.G., et al. Liver transplantation for hereditary tyrosinemia: the Quebec experience. Am J Hum Genet 1990, 47:338-342.
7. Buyukpamukcu M., Varan A., Haberal M., et al. The efficacy of liver transplantation in malignant liver tumors associated with tyrosinemia: clinical and laboratory findings of five cases. Pediatr Transplant 2006, 10:517-520.
8. van Spronsen F.J., Berger R., Smit G.P., et al. Tyrosinaemia type I: orthotopic liver transplantation as the only definitive answer to a metabolic as well as an oncological problem. J Inherit Metab Dis 1989, 12(Suppl 2):339-342.
9. Lindstedt S., Holme E., Lock E.A., Hjalmarson O., Strandvik B. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 1992, 340:813-817.
10. El-Karaksy H., Rashed M., El-Sayed R., et al. Clinical practice. NTBC therapy for tyrosinemia type 1: how much is enough?. Eur J Pediatr 2010, 169:689-693.
11. Bielenstein M., Astner L., Ekberg S. Determination of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione in plasma by direct injection into a coupled column liquid chromatographic system. J Chromatogr B Biomed Sci Appl 1999, 730:177-182.
12. Cansever M.S., Aktuglu-Zeybek A.C., Erim F.B. Determination of NTBC in serum samples from patients with hereditary tyrosinemia type I by capillary electrophoresis. Talanta 2010, 80:1846-1848.
13. Herebian D., Spiekerkotter U., Lamshoft M., Thimm E., Laryea M., Mayatepek E. Liquid chromatography tandem mass spectrometry method for the quantitation of NTBC (2-(nitro-4-trifluoromethylbenzoyl)1,3-cyclohexanedione) in plasma of tyrosinemia type 1 patients. J Chromatogr B Anal Technol Biomed Life Sci 2009, 877:1453-1459.
14. Sander J., Janzen N., Peter M., et al. Newborn screening for hepatorenal tyrosinemia: tandem mass spectrometric quantification of succinylacetone. Clin Chem 2006, 52:482-487.
15. Chace D.H., Kalas T.A., Naylor E.W. Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns. Clin Chem 2003, 49:1797-1817.
16. National Committee for Clinical Laboratory S, Evaluation of precision performance of quantitative measurement methods: approved guideline, 2nd ed ed. Wayne, PA: NCCLS, 2/2004.
17. Hall M.G., Wilks M.F., Provan W.M., Eksborg S., Lumholtz B. Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers. Br J Clin Pharmacol 2001, 52:169-177.
18. Allard P., Grenier A., Korson M.S., Zytkovicz T.H. Newborn screening for hepatorenal tyrosinemia by tandem mass spectrometry: analysis of succinylacetone extracted from dried blood spots. Clin Biochem 2004, 37:1010-1015.
19. Al-Dirbashi O.Y., Rashed M.S., Brink H.J., et al. Determination of succinylacetone in dried blood spots and liquid urine as a dansylhydrazone by liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2006, 831:274-280.
20. Turgeon C., Magera M.J., Allard P., et al. Combined newborn screening for succinylacetone, amino acids, and acylcarnitines in dried blood spots. Clin Chem 2008, 54:657-664.
21. Chace D.H., Lim T., Hansen C.R., De Jesus V.R., Hannon W.H. Improved MS/MS analysis of succinylacetone extracted from dried blood spots when combined with amino acids and acylcarnitine butyl esters. Clin Chim Acta 2009, 407:6-9.
22. la Marca G., Malvagia S., Pasquini E., et al. The inclusion of succinylacetone as marker for tyrosinemia type I in expanded newborn screening programs. Rapid Commun Mass Spectrom 2008, 22:812-818.